Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene has earned a respected four-star ranking.
With that in mind, let's take a closer look at Celgene, and see what CAPS investors are saying about the stock right now.
Summit, N.J. (1980)
Chairman/CEO Robert Hugin
CFO Jacqualyn Fouse
Return on Equity (average, past 3 years)
Cash / Debt
$3.8 billion / $3.1 billion
Johnson & Johnson
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 1,594 members who have rated Celgene believe the stock will outperform the S&P 500 going forward.
High expected earnings growth, extremely profitable, still attractive valuation. Core holding in health care business.
Of course, that short pitch doesn't even come close to telling the entire story for Celgene. You're in luck, though. The Fool's brand-new premium report on Celgene looks at all sides of one of the most compelling biotechnology companies in the world. You can grab your copy, which comes with free updates for 12 months.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Celgene Is Poised to Keep Popping originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.